|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DICER1 |
Gene summary for DICER1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DICER1 | Gene ID | 23405 |
| Gene name | dicer 1, ribonuclease III | |
| Gene Alias | DCR1 | |
| Cytomap | 14q32.13 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9UPY3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23405 | DICER1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.47e-19 | -7.45e-01 | 0.0155 |
| 23405 | DICER1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.05e-11 | -7.45e-01 | -0.1808 |
| 23405 | DICER1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.71e-03 | -8.31e-01 | 0.0216 |
| 23405 | DICER1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.86e-08 | -7.24e-01 | -0.0811 |
| 23405 | DICER1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.44e-08 | -7.41e-01 | -0.1207 |
| 23405 | DICER1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.81e-02 | -5.03e-01 | -0.1526 |
| 23405 | DICER1 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.28e-16 | -5.37e-01 | -0.1464 |
| 23405 | DICER1 | HTA11_866_2000001011 | Human | Colorectum | AD | 6.71e-17 | -6.20e-01 | -0.1001 |
| 23405 | DICER1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.91e-02 | -4.51e-01 | -0.059 |
| 23405 | DICER1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 6.56e-03 | -7.35e-01 | -0.1706 |
| 23405 | DICER1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.72e-04 | -7.75e-01 | -0.2061 |
| 23405 | DICER1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.33e-02 | -5.94e-01 | -0.0179 |
| 23405 | DICER1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.75e-15 | -7.21e-01 | 0.096 |
| 23405 | DICER1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 9.33e-04 | -7.15e-01 | 0.0528 |
| 23405 | DICER1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 6.56e-09 | -7.15e-01 | 0.0338 |
| 23405 | DICER1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.73e-19 | -5.96e-01 | 0.0674 |
| 23405 | DICER1 | HTA11_6818_2000001011 | Human | Colorectum | AD | 3.56e-02 | -6.07e-01 | 0.0112 |
| 23405 | DICER1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.66e-04 | -5.99e-01 | 0.0588 |
| 23405 | DICER1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.63e-15 | -5.29e-01 | 0.294 |
| 23405 | DICER1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.67e-36 | -7.63e-01 | 0.3859 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00905022 | Oral cavity | OSCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 44/7305 | 82/18723 | 4.95e-03 | 1.94e-02 | 44 |
| GO:00160781 | Oral cavity | OSCC | tRNA catabolic process | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
| GO:00162463 | Oral cavity | OSCC | RNA interference | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
| GO:000640124 | Oral cavity | EOLP | RNA catabolic process | 77/2218 | 278/18723 | 3.92e-13 | 1.12e-10 | 77 |
| GO:007182626 | Oral cavity | EOLP | ribonucleoprotein complex subunit organization | 62/2218 | 227/18723 | 1.42e-10 | 1.52e-08 | 62 |
| GO:002261826 | Oral cavity | EOLP | ribonucleoprotein complex assembly | 59/2218 | 220/18723 | 8.55e-10 | 6.25e-08 | 59 |
| GO:003465523 | Oral cavity | EOLP | nucleobase-containing compound catabolic process | 89/2218 | 407/18723 | 5.47e-09 | 2.92e-07 | 89 |
| GO:002241121 | Oral cavity | EOLP | cellular component disassembly | 94/2218 | 443/18723 | 1.00e-08 | 4.89e-07 | 94 |
| GO:002261326 | Oral cavity | EOLP | ribonucleoprotein complex biogenesis | 96/2218 | 463/18723 | 2.34e-08 | 9.81e-07 | 96 |
| GO:004670023 | Oral cavity | EOLP | heterocycle catabolic process | 93/2218 | 445/18723 | 2.61e-08 | 1.08e-06 | 93 |
| GO:004427023 | Oral cavity | EOLP | cellular nitrogen compound catabolic process | 92/2218 | 451/18723 | 1.01e-07 | 3.45e-06 | 92 |
| GO:001943923 | Oral cavity | EOLP | aromatic compound catabolic process | 92/2218 | 467/18723 | 5.23e-07 | 1.40e-05 | 92 |
| GO:190136123 | Oral cavity | EOLP | organic cyclic compound catabolic process | 95/2218 | 495/18723 | 1.15e-06 | 2.80e-05 | 95 |
| GO:001072021 | Oral cavity | EOLP | positive regulation of cell development | 59/2218 | 298/18723 | 4.72e-05 | 6.25e-04 | 59 |
| GO:003519622 | Oral cavity | EOLP | production of miRNAs involved in gene silencing by miRNA | 16/2218 | 52/18723 | 2.25e-04 | 2.22e-03 | 16 |
| GO:003806121 | Oral cavity | EOLP | NIK/NF-kappaB signaling | 32/2218 | 143/18723 | 2.64e-04 | 2.56e-03 | 32 |
| GO:003105022 | Oral cavity | EOLP | dsRNA processing | 16/2218 | 54/18723 | 3.63e-04 | 3.32e-03 | 16 |
| GO:007091822 | Oral cavity | EOLP | production of small RNA involved in gene silencing by RNA | 16/2218 | 54/18723 | 3.63e-04 | 3.32e-03 | 16 |
| GO:005076912 | Oral cavity | EOLP | positive regulation of neurogenesis | 42/2218 | 225/18723 | 1.83e-03 | 1.19e-02 | 42 |
| GO:005076712 | Oral cavity | EOLP | regulation of neurogenesis | 61/2218 | 364/18723 | 3.20e-03 | 1.86e-02 | 61 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DICER1 | SNV | Missense_Mutation | novel | c.4430C>G | p.Ser1477Cys | p.S1477C | Q9UPY3 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.733) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| DICER1 | SNV | Missense_Mutation | c.3037N>A | p.Pro1013Thr | p.P1013T | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| DICER1 | SNV | Missense_Mutation | c.2326N>T | p.Val776Phe | p.V776F | Q9UPY3 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DICER1 | SNV | Missense_Mutation | c.5240N>T | p.Ser1747Leu | p.S1747L | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| DICER1 | SNV | Missense_Mutation | novel | c.1490N>C | p.Glu497Ala | p.E497A | Q9UPY3 | protein_coding | tolerated(0.06) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DICER1 | SNV | Missense_Mutation | c.2084C>T | p.Ala695Val | p.A695V | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DICER1 | SNV | Missense_Mutation | novel | c.322N>G | p.Gln108Glu | p.Q108E | Q9UPY3 | protein_coding | tolerated(0.59) | benign(0.055) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| DICER1 | SNV | Missense_Mutation | rs752424727 | c.1778C>T | p.Ser593Leu | p.S593L | Q9UPY3 | protein_coding | tolerated(0.2) | benign(0.033) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DICER1 | SNV | Missense_Mutation | c.4529N>A | p.Cys1510Tyr | p.C1510Y | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| DICER1 | SNV | Missense_Mutation | c.4018G>C | p.Glu1340Gln | p.E1340Q | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |